Senegal vs United States of America: Proportion of the target population who received the final dose of
Senegal
51.0%
in 2024
United States of America
52.0%
in 2024
Senegal rank
73rd
United States of America rank
71st
Proportion of the target population who received the final dose of over time
- Senegal
- United States of America
How they compare
United States of America currently reports 52.0% against 51.0% in Senegal, a difference of 1.0%.
Across all 6 years both countries report, United States of America has been ahead every year.
Senegal ranks 73rd and United States of America ranks 71st of 107 countries.
United States of America has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Senegal | United States of America | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 26.0% | 49.0% | 23.0% | United States of America |
| 2020s | 36.6% | 50.8% | 14.2% | United States of America |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Senegal or United States of America?
- United States of America, at 52.0% against 51.0% in Senegal as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Senegal and United States of America?
- 1.0%, with United States of America ahead.
- How many years of comparable data are there for Senegal and United States of America?
- 6 years are reported by both, from 2019 to 2024.
- How do Senegal and United States of America rank globally for proportion of the target population who received the final dose of?
- Senegal ranks 73rd and United States of America ranks 71st of 107 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.